Cargando…

The OECD program to validate the rat uterotrophic bioassay. Phase 2: coded single-dose studies.

The Organisation for Economic Co-operation and Development has completed phase 2 of an international validation program for the rodent uterotrophic bioassay. This portion of phase 2 assessed the reproducibility of the assay with a battery of positive and negative test substances. Positive agonists o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanno, Jun, Onyon, Lesley, Peddada, Shyamal, Ashby, John, Jacob, Elard, Owens, William
Formato: Texto
Lenguaje:English
Publicado: 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1241660/
https://www.ncbi.nlm.nih.gov/pubmed/12948897
_version_ 1782125468272558080
author Kanno, Jun
Onyon, Lesley
Peddada, Shyamal
Ashby, John
Jacob, Elard
Owens, William
author_facet Kanno, Jun
Onyon, Lesley
Peddada, Shyamal
Ashby, John
Jacob, Elard
Owens, William
author_sort Kanno, Jun
collection PubMed
description The Organisation for Economic Co-operation and Development has completed phase 2 of an international validation program for the rodent uterotrophic bioassay. This portion of phase 2 assessed the reproducibility of the assay with a battery of positive and negative test substances. Positive agonists of the estrogen receptor included the potent reference estrogen 17-ethinyl estradiol (EE), and the weak estrogen agonists bisphenol A, genistein, methoxychlor, nonylphenol, and o,p -DDT. The negative test substance or nonagonist was n-dibutylphthalate. The test substances were coded, and prescribed doses of each test substance were administered in 16 laboratories. Two versions of the uterotrophic assay, the intact immature and the adult ovariectomized female rat, were tested and compared using four standardized protocols covering both sc and po administration. Assay reproducibility was compared using a) EE doses identical to those used in phase 1 and in parallel dose-response studies, b) single doses of the weak agonists identical to one of five doses from the dose-response studies, and c) a single dose of the negative test substance. The results were reproducible and in agreement both within individual laboratories and across the participating laboratories for the same test substance and protocol. The few exceptions are examined in detail. The reproducibility was achieved despite a variety of different experimental conditions (e.g., variations in animal strain, diet, housing protocol, bedding, vehicle, animal age). In conclusion, both versions of the uterotrophic bioassay and all protocols appear robust, reproducible, and transferable across laboratories and able to detect weak estrogen agonists. These results will be submitted along with other data for independent peer review to provide support for the validation of the uterotrophic bioassay.
format Text
id pubmed-1241660
institution National Center for Biotechnology Information
language English
publishDate 2003
record_format MEDLINE/PubMed
spelling pubmed-12416602005-11-08 The OECD program to validate the rat uterotrophic bioassay. Phase 2: coded single-dose studies. Kanno, Jun Onyon, Lesley Peddada, Shyamal Ashby, John Jacob, Elard Owens, William Environ Health Perspect Research Article The Organisation for Economic Co-operation and Development has completed phase 2 of an international validation program for the rodent uterotrophic bioassay. This portion of phase 2 assessed the reproducibility of the assay with a battery of positive and negative test substances. Positive agonists of the estrogen receptor included the potent reference estrogen 17-ethinyl estradiol (EE), and the weak estrogen agonists bisphenol A, genistein, methoxychlor, nonylphenol, and o,p -DDT. The negative test substance or nonagonist was n-dibutylphthalate. The test substances were coded, and prescribed doses of each test substance were administered in 16 laboratories. Two versions of the uterotrophic assay, the intact immature and the adult ovariectomized female rat, were tested and compared using four standardized protocols covering both sc and po administration. Assay reproducibility was compared using a) EE doses identical to those used in phase 1 and in parallel dose-response studies, b) single doses of the weak agonists identical to one of five doses from the dose-response studies, and c) a single dose of the negative test substance. The results were reproducible and in agreement both within individual laboratories and across the participating laboratories for the same test substance and protocol. The few exceptions are examined in detail. The reproducibility was achieved despite a variety of different experimental conditions (e.g., variations in animal strain, diet, housing protocol, bedding, vehicle, animal age). In conclusion, both versions of the uterotrophic bioassay and all protocols appear robust, reproducible, and transferable across laboratories and able to detect weak estrogen agonists. These results will be submitted along with other data for independent peer review to provide support for the validation of the uterotrophic bioassay. 2003-09 /pmc/articles/PMC1241660/ /pubmed/12948897 Text en
spellingShingle Research Article
Kanno, Jun
Onyon, Lesley
Peddada, Shyamal
Ashby, John
Jacob, Elard
Owens, William
The OECD program to validate the rat uterotrophic bioassay. Phase 2: coded single-dose studies.
title The OECD program to validate the rat uterotrophic bioassay. Phase 2: coded single-dose studies.
title_full The OECD program to validate the rat uterotrophic bioassay. Phase 2: coded single-dose studies.
title_fullStr The OECD program to validate the rat uterotrophic bioassay. Phase 2: coded single-dose studies.
title_full_unstemmed The OECD program to validate the rat uterotrophic bioassay. Phase 2: coded single-dose studies.
title_short The OECD program to validate the rat uterotrophic bioassay. Phase 2: coded single-dose studies.
title_sort oecd program to validate the rat uterotrophic bioassay. phase 2: coded single-dose studies.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1241660/
https://www.ncbi.nlm.nih.gov/pubmed/12948897
work_keys_str_mv AT kannojun theoecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies
AT onyonlesley theoecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies
AT peddadashyamal theoecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies
AT ashbyjohn theoecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies
AT jacobelard theoecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies
AT owenswilliam theoecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies
AT kannojun oecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies
AT onyonlesley oecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies
AT peddadashyamal oecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies
AT ashbyjohn oecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies
AT jacobelard oecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies
AT owenswilliam oecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies